Irit Orr
Weizmann Institute of Science
11 Papers
66 Citations
Irit Orr is an academic researcher from Weizmann Institute of Science. The author has contributed to research in topics: Biology & Cytotoxic T cell. The author has an hindex of 7, co-authored 8 publications.
Chat about Author
Papers
CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia
Hadas Lewinsky,Avital F. Barak,Victoria Huber,Matthias P. Kramer,Lihi Radomir,Lital Sever,Irit Orr,Vita Mirkin,Nili Dezorella,Mika Shapiro,Yosef Cohen,Lev Shvidel,Martina Seiffert,Yair Herishanu,Shirly Becker-Herman,Idit Shachar +15 more
TL;DR: A role for CD84 is demonstrated in the regulation of immune checkpoints by leukemia cells and CD84 blockade is identified as a therapeutic strategy to reverse tumor-induced immune suppression.
Ndel1 palmitoylation: a new mean to regulate cytoplasmic dynein activity
Anat Shmueli,Michal Segal,Tamar Sapir,Ryouhei Tsutsumi,Jun Noritake,Avi Bar,Sivan Sapoznik,Yuko Fukata,Yuko Fukata,Irit Orr,Masaki Fukata,Masaki Fukata,Orly Reiner +12 more
TL;DR: These findings indicate, to the best of the knowledge, for the first time that Ndel1 palmitoylation is a new mean for fine‐tuning the activity of the retrograde motor cytoplasmic dynein.
52
Genomic profiling of bovine corpus luteum maturation.
TL;DR: The data suggests day 11 CL acquire mechanisms to prevent blood vessel sprouting and promote their maturation by expressing NOTCH4 and JAG1, greatly enriched in luteal endothelial cells, providing new insight of the processes involved in CL maturation including blood vessel growth and stabilization, leucocyte transmigration as well as progesterone synthesis as the CL matures.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis
TL;DR: A robust blood-derived type I IFN gene signature from MS patients is defined that could potentially serve to generically quantify the systemic Type I IFn activation status for any other clinical manifestation, inclusive of other autoimmune diseases.
Temporal genomic analysis of melanoma rejection identifies regulators of tumor immune evasion
Sapir Cohen Shvefel,Joy A. Pai,Yingying Cao,Lipika R. Pal,Ron Levy,Winnie Yao,Kuoyuan Cheng,Marie Zemanek,Osnat Bartok,Chen Weller,Yajie Yin,Peter P. Du,Elizabeta Yakubovich,Irit Orr,Shifra Ben-Dor,Roni Oren,Liat Fellus-Alyagor,Ofra Golani,Inna Goliand,Dean Ranmar,Ilya Savchenko,Nadav Ketrarou,Alejandro A. Schäffer,E. Ruppin,,Ansuman T. Satpathy,Yardena Samuels +25 more
TL;DR: The association of Mif expression with tumor growth and aggressiveness is uncovered, specifically in low ITH tumors, which could facilitate the development of new strategies to treat patients with homogeneous, high-MIF expressing tumors that are unresponsive to immune checkpoint therapy.
1